TriLink BioTechnologies, 10770 Wateridge Circle, Suite 200, San Diego, CA, 92121, USA.
Anal Biochem. 2022 May 1;644:113894. doi: 10.1016/j.ab.2020.113894. Epub 2020 Aug 5.
Aptamers are typically defined as relatively short (20-60 nucleotides) single-stranded DNA or RNA molecules that bind with high affinity and specificity to various types of targets. Aptamers are frequently referred to as "synthetic antibodies" but are easier to obtain, less expensive to produce, and in several ways more versatile than antibodies. The beginnings of aptamers date back to 1990, and since then there has been a continual increase in aptamer publications. The intent of the present account was to focus on recent original research publications, i.e., those appearing in 2019 through April 2020, when this account was written. A Google Scholar search of this recent literature was performed for relevance-ranking of articles. New methods for selection of aptamers were not included. Nine categories of applications were organized and representative examples of each are given. Finally, an outlook is offered focusing on "faster, better, cheaper" application performance factors as key drivers for future innovations in aptamer applications.
适体通常被定义为相对较短（20-60 个核苷酸）的单链 DNA 或 RNA 分子，能够与各种类型的靶标结合，具有高亲和力和特异性。适体通常被称为“合成抗体”，但比抗体更容易获得、成本更低、在多个方面更具多功能性。适体的起源可以追溯到 1990 年，自那时以来，适体的出版物数量一直在持续增加。本报告的目的是重点关注最近的原创研究出版物，即 2019 年至 2020 年 4 月期间发表的出版物。在撰写本报告时，对该最新文献进行了谷歌学术搜索，以对文章进行相关性排名。未包括适体选择的新方法。将应用分为九个类别，并给出每个类别的代表性示例。最后，着眼于“更快、更好、更便宜”的应用性能因素，提供了对适体应用未来创新的展望。
